Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know.
about
Nosocomial spread of a Staphylococcus capitis strain with heteroresistance to vancomycin in a neonatal intensive care unit.Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazoleReduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsReview of vancomycin-induced renal toxicity: an updateSystematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus IsolatesStructural features and kinetic characterization of alanine racemase fromStaphylococcus aureus(Mu50)In vitro activity of thiamphenicol against multiresistant Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus in ItalyVancomycin-intermediate Staphylococcus aureus in a home health-care patientIn vitro and ex vivo activities of minocycline and EDTA against microorganisms embedded in biofilm on catheter surfacesEfficient photodynamic therapy against gram-positive and gram-negative bacteria using THPTS, a cationic photosensitizer excited by infrared wavelengthManagement of community-associated methicillin-resistant Staphylococcus aureus infections in children.Analysis of vancomycin use and associated risk factors in a university teaching hospital: a prospective cohort study.Molecular features of heterogeneous vancomycin-intermediate Staphylococcus aureus strains isolated from bacteremic patientsPhotodynamic effects of novel XF porphyrin derivatives on prokaryotic and eukaryotic cells.Nationwide antibiogram analysis using NCCLS M39-A guidelines.Vancomycin resistance in staphylococci.Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycinVancomycin susceptibility of oxacillin-resistant Staphylococcus aureus isolates causing nosocomial bloodstream infections.Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia.Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysis7-O-malonyl macrolactin A, a new macrolactin antibiotic from Bacillus subtilis active against methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and a small-colony variant of Burkholderia cepaciaCell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureusQuinupristin/dalfopristin.A play in four acts: Staphylococcus aureus abscess formationAntimicrobial-resistant, Gram-positive bacteria among patients undergoing chronic hemodialysis.Vancomycin-resistant Staphylococcus aureus isolate from a patient in PennsylvaniaInfluence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis.Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.A report on the first case of vancomycin-intermediate Staphylococcus aureus (VISA) in Hawai'iThe photodynamic antibacterial effects of silicon phthalocyanine (Pc) 4Confronting bacterial resistance in healthcare settings: a crucial role for microbiologists.Minimal inhibitory concentration of microorganisms causing surgical site infection in referral hospitals in North of Iran, 2011-2012.Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care centerPredictors of mortality in Staphylococcus aureus BacteremiaMethicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci co-colonizationEarly use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trialNosocomial bacterial infections in Intensive Care Units. I: Organisms and mechanisms of antibiotic resistance.Prevention of Staphylococcus aureus infections: advances in vaccine development.Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.The pharmacokinetic and pharmacodynamic properties of vancomycin.
P2860
Q24532922-114A55EC-3810-42DC-A9B2-FFCACD76DCCCQ24620644-413B301A-4477-4285-AC59-C1B0D7596C2BQ24646677-FB9DD107-4B17-430B-844D-335262D594DAQ26746932-33DC8405-A6AF-4F13-B13D-028AA7444A1BQ26796560-775EA55D-D713-4B91-8845-7F7F930EE826Q27676379-5062AA24-D4DB-43AC-AE2A-7621B8414946Q28209003-C2A62B27-3A10-4774-9AC5-6029D7659687Q28366629-A8ABCABD-3267-4550-9960-9156C9B0DA66Q28385700-06220DF2-9FC9-4CAD-AE47-29CB534CEDE1Q28474872-BE81E969-B85D-49F7-B393-A89F53118C91Q33264579-00E1FE7E-E00F-406C-A99A-380D917A7A3EQ33293228-89830583-0326-448D-860D-F63E5FE6ADEFQ33500363-3784DBC2-6595-4A53-8BC5-9CA4FBDE0CF9Q33722039-A15F403D-2352-4701-A911-FE9CF28CA06FQ33856293-3F2FA9E0-E411-4F80-BF43-DA425D0D67ADQ33906522-E0EC88C7-F497-4BC7-A0F2-37C4E12674ECQ34107062-C6807FB9-677E-4F28-ABDD-B9CE7EB22325Q34198417-0A1FE610-6F4B-4094-9EF8-216EE2824F70Q34396414-F1C4CD49-C48D-41B3-886F-69F3696CF0F4Q34405301-F87308CD-903B-420A-8D73-F46DC48691E3Q34648847-59C99238-6EEE-45FD-A0B4-BDA660789162Q34747322-66CF81D6-3602-4EE0-9B67-7ECC083A1843Q34789160-F599D6AB-2354-4D9D-8C73-0D1B6201EF70Q34928131-8D47F579-F0BD-49FC-934E-E2063A41ECB0Q34985828-4751308F-7B26-4858-9BDF-831622DAECDDQ35007120-1E19F7D1-6605-469F-99BE-F9EDE53CE4EBQ35014464-4C446A3D-C240-4F51-919B-E54F7521DD34Q35541702-A4EC84DF-0B6F-41AB-ADF0-0F149389F8DCQ35549808-04859CAC-8EB2-49E1-9708-89207656A5EBQ35585561-6ABB85C1-6CA8-488A-B423-FE5D1C9BC9EEQ35745242-CFB58B3A-6C0D-49EE-931A-769F308916A9Q35772283-F6B961B9-0B15-40AD-9778-E651AAB89407Q35784453-7EBE6155-97A0-446C-8280-83322A693B74Q35940556-858F481C-5EF5-4F6C-8A90-95531FE78242Q36006718-C218263D-EC47-423D-ABE9-2B35C145DC78Q36093598-A172638D-8941-447E-B2F2-D5266A7BA35FQ36237707-D69B73A0-8D42-4844-8C29-51715ABB511DQ36284548-0004EAB0-1E86-4332-B0B5-9F53843EAC0EQ36328966-DD86853F-26F8-4692-8AAF-6EF418C6D2E8Q36328971-8D36659E-4EA1-49EA-8363-222BBC635D7E
P2860
Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Vancomycin-intermediate and -r ...... ease specialist needs to know.
@ast
Vancomycin-intermediate and -r ...... ease specialist needs to know.
@en
type
label
Vancomycin-intermediate and -r ...... ease specialist needs to know.
@ast
Vancomycin-intermediate and -r ...... ease specialist needs to know.
@en
prefLabel
Vancomycin-intermediate and -r ...... ease specialist needs to know.
@ast
Vancomycin-intermediate and -r ...... ease specialist needs to know.
@en
P2860
P356
P1476
Vancomycin-intermediate and -r ...... ease specialist needs to know.
@en
P2093
Fridkin SK
P2860
P304
P356
10.1086/317542
P407
P577
2000-12-13T00:00:00Z